14 completed, 4 recruiting, 3 unknown, 2 not yet recruiting. 10 Not applicable, 6 Phase 2, 5 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow Inosine Monophosphate: new trials by email Literature Review of Inosine Monophosphate trials Research Report on Inosine Monophosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET/MRI FAPI tracer - Sarcoma | Phase 2 | Not yet recruiting | Copenhagen University Hospital, Rigshospitalet | 40 | 2026-12-01 | 2026-10-06 |
| A Clinical Trial of GRT7040 in Adults With Acute Pain Following Bunionectomy GRT7040, Hydrocodone bitartrate/ acetaminophen (HB/APAP), Placebo (matched to HB/APAP) - Acute Pain, Bunionectomy | Phase 2 | Not yet recruiting | Grünenthal GmbH | 400 | 2026-09-01 | 2026-09-15 |
| Outpatient Induction of Labour Using a Double Balloon Transcervical Catheter in Low-risk Pregnant Women: a Two-centre Open Prospective Randomised Controlled Trial - OutCRIB Outpatient, Inpatient - Pregnant Women | Not applicable | Recruiting | Nantes University Hospital | 258 | 2026-04-30 | 2026-05-07 |
| Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3 - Respiratory Syncytial Virus (RSV), Influenza A(H5N1) | Phase 1 | Recruiting | Sanofi | 570 | 2026-04-15 | 2026-05-08 |
| Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123 - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Enrolling by invitation | AvenCell Therapeutics, Inc. | 178 | 2026-01-29 | 2026-03-16 | |
| Effect of a Health Pathway for People With Persistent Symptoms Covid-19 usual care and follow-up by a nurse, Personalized Multifactorial Intervention (IMP) - COVID-19 | Not applicable | Active not recruiting | Centre Hospitalier Universitaire de Saint Etienne | 400 | 2023-11-15 | 2026-05-06 |
| Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® IMP, Placebo - Surgical Site Infection, Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Unknown | MB PHARMA s.r.o. | 52 | 2023-10-27 | 2024-03-19 |
| Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics Inpatient or Outpatient visit - Respiratory Disease, Cardiovascular Diseases | Recruiting | IRCCS San Raffaele | 50000 | 2022-06-24 | 2025-06-22 | |
| Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study) Feel-Good- Group - Early Psychosis, Delusions | Early Phase 1 | Completed | Philipps University Marburg | 36 | 2021-01-08 | 2022-05-05 |
| Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), UniCAR02-T-pPSMA - Prostate Cancer | Phase 1 | Terminated | AvenCell Europe GmbH | 16 | 2020-11-23 | 2024-04-23 |
| Inpatient vs Outpatient Total Knee Replacement Outpatient, Inpatient - Osteoarthritis, Knee | Not applicable | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 123 | 2020-10-22 | 2025-03-06 |
| Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP) - Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | AvenCell Europe GmbH | 32 | 2020-01-28 | 2026-01-22 |
| Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial BRAP (Bevel/rotate/advance procedure), Trabut - Trichiasis, Surgery | Not applicable | Completed | University of North Carolina, Chapel Hill | 886 | 2019-04-13 | 2024-02-22 |
| Inpatient Versus Outpatient Foley Cervical Ripening Study Outpatient, Inpatient - Induced; Birth | Not applicable | Completed | Yale University | 54 | 2019-01-08 | 2023-02-22 |
| Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial 1) Inosine 5'-monophosphate, Placebo - Multiple System Atrophy | Phase 2 | Completed | Yonsei University | 43 | 2018-05-02 | 2019-07-08 |
| Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies Investigational medical product (IMP) administered in parent study - Osteoarthritis, Cancer Pain | Phase 3 | Completed | Pfizer | 4 | 2017-11-03 | 2021-06-25 |
| Evaluation of Impression Accuracy: Digital Scanner Versus Analog Technique impression, Digital impression - Accuracy and Precision of Noninvasive Measurement | Completed | University of Milan | 51 | 2017-07-15 | 2025-11-28 | |
| Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement Investigational Medical Product (IMP) administered in parent study - Osteoarthritis | Phase 3 | Completed | Pfizer | 154 | 2016-08-23 | 2020-07-30 |
| Intraoral Impressions for Assessment of Wear of Teeth and Restorative Materials. impression - Wear, Tooth, Wear, Occlusal | Unknown | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 33 | 2016-02-01 | 2018-08-10 | |
| Incidence and Risk Factor of Drug Related Problem Detected in Inpatient Detection of drug related problem in inpatient - Drug Related Problem | Recruiting | University Hospital, Montpellier | 20000 | 2016-01-01 | 2020-06-05 |
Showing 20 of 27. Sign in to see all of them.
Osteoarthritis (3) · Leukemia, Myeloid, Acute (2) · Personal Satisfaction (2) · Prostatic Neoplasms (2) · Acute Pain (1) · Bacterial Infections (1) · COVID-19 (1) · Cancer Pain (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Communicable Diseases (1) · Coronary Artery Disease (1) · Critical Illness (1) · Delusions (1) · Dissociative Identity Disorder (1)
AvenCell Europe GmbH (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Pfizer (2) · AHEPA University Hospital (1) · AvenCell Therapeutics, Inc. (1) · Cedars-Sinai Medical Center (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Copenhagen University Hospital, Rigshospitalet (1) · Grünenthal GmbH (1) · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio (1) · IRCCS San Raffaele (1) · MB PHARMA s.r.o. (1) · Nantes University Hospital (1) · Oslo University Hospital (1) · Peking Union Medical College Hospital (1)
Germany (5) · United States (4) · Canada (3) · France (3) · Italy (3) · Australia (2) · China (1) · Czechia (1) · Denmark (1) · Ethiopia (1) · Greece (1) · Hungary (1) · Ireland (1) · Japan (1) · Lithuania (1)
Brent Lanting, MD, FRCSC (2) · Andreas Bechdolf, MD (1) · Emily Gower, PhD (1) · Jelena Kisic-Trope, MD, Msc (1) · John R Higgins, MD (1) · Karolina Leopold, MD (1) · Katherine Kohari, MD (1) · Kyriakos Anastasiadis, MD, PhD FETCS (1) · Nikola M Stenzel, Ph. D. (1) · Ralf Bargou, Prof. (1)
PMID 32462078, PMID 32852803, PMID 33032566, PMID 34043229, PMID 34105902, PMID 35966482, PMID 36186856, PMID 36302128, PMID 39435124, PMID 40301772
2019 (2), 2025 (2), UG1EY025992-04S1 (1)